FOLH1 and neoplasm: The conjugation with truncated EB resulted in improved tumor uptake and pharmacokinetics using 177Lu-labeled tumor targeting vectors specific for somatostatin receptors (EB-TATE), integrin αvβ3 (EB-cRGD), prostate-specific membrane antigen (EB-PSMA-617), and glucagon-like peptide-1 receptor (EB-exendin-4) [24,30,31,32].